BIOMAT Database Logo BIOMAT Database Logo

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. 2013

Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
Hospital Carlos III, Madrid, Spain. lourdes.anta@hotmail.es

OBJECTIVE Limited data are available on resistance to etravirine, rilpivirine, darunavir and tipranavir in patients infected with HIV-1 non-B subtypes, in which natural polymorphisms at certain positions could influence the barrier and/or pathways to drug resistance. METHODS FASTA format sequences from the reverse transcriptase and protease genes recorded within the Spanish Drug Resistance database (ResRIS) were examined. RESULTS From 8272 genotypes derived from 5930 different HIV-1 patients included in ResRIS, 5276 genotypes had complete treatment information. Overall, 85% were from antiretroviral-experienced subjects and 7.5% belonged to HIV-1 non-B subtypes: CRF02_AG, C, F and G being the most prevalent variants. For etravirine, only G190A was more prevalent in B than non-B subtypes, whereas V90I and V179E were more frequent in non-B than B subtypes. For rilpivirine, V108I and Y188I were more frequent in B than non-B subtypes, whereas V90I was more prevalent in non-B subtypes. Despite these differences, the overall prevalence of resistance did not differ significantly when comparing etravirine or rilpivirine in B versus non-B subtypes (11.3% versus 7.4%, P = 0.13, and 10.5% versus 7.4%, P = 0.23, respectively). Despite more frequent natural polymorphisms in non-B than B subtypes at tipranavir resistance positions, the prevalence of tipranavir resistance was greater in B than non-B subtypes (11% versus 4.3%, P = 0.004), reflecting a greater antiretroviral exposure in the former. Darunavir resistance did not differ significantly when comparing B and non-B subtypes (5.8% versus 5.5%, P = 0.998). CONCLUSIONS The rate of resistance to the most recently approved protease and non-nucleoside reverse transcriptase inhibitors is low in antiretroviral-experienced patients, regardless of the HIV-1 subtype.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013030 Spain Country located between France on the northeast and Portugal on the west and bordered by the Atlantic Ocean and the Mediterranean Sea. The capital is Madrid. Balearic Islands,Canary Islands
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
[HIV resistance to non-nucleoside reverse transcriptase inhibitors].
August 2006, Virologie (Montrouge, France),
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
[Mechanisms of HIV-1 drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors].
January 2011, Molekuliarnaia biologiia,
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
January 2009, AIDS reviews,
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
In silico screening of HIV-1 non-nucleoside reverse transcriptase and protease inhibitors.
July 2008, European journal of medicinal chemistry,
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
[Resistance to non-nucleoside reverse transcriptase inhibitors].
February 2001, Enfermedades infecciosas y microbiologia clinica,
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.
September 2003, Journal of acquired immune deficiency syndromes (1999),
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
June 2003, AIDS (London, England),
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
June 2008, Journal of HIV therapy,
Lourdes Anta, and José L Blanco, and Josep M Llibre, and Federico García, and María J Pérez-Elías, and Antonio Aguilera, and Pilar Pérez-Romero, and Estrella Caballero, and Carmen Vidal, and Angelina Cañizares, and Félix Gutiérrez, and David Dalmau, and José A Iribarren, and Vicente Soriano, and Carmen de Mendoza, and
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Copied contents to your clipboard!